<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="acn352010" xml:lang="en" article-type="brief-report">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id><journal-id journal-id-type="publisher-id">ACN3</journal-id><journal-title-group><journal-title>Annals of Clinical and Translational Neurology</journal-title></journal-title-group><issn pub-type="epub">2328-9503</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38282243</article-id><article-id pub-id-type="pmc">11021635</article-id>
<article-id pub-id-type="doi">10.1002/acn3.52010</article-id><article-id pub-id-type="publisher-id">ACN352010</article-id><article-id pub-id-type="other">ACN3-2023-09-0753-BC.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Communication</subject></subj-group></article-categories><title-group><article-title>Astroglial conditional <italic toggle="no">Slc13a3</italic> knockout is therapeutic in murine Canavan leukodystrophy</article-title><alt-title alt-title-type="right-running-head">Astroglia in Canavan Disease</alt-title><alt-title alt-title-type="left-running-head">V. L. Hull <italic toggle="no">et&#xA0;al.</italic>
</alt-title></title-group><contrib-group><contrib id="acn352010-cr-0001" contrib-type="author"><name><surname>Hull</surname><given-names>Vanessa L.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3221-740X</contrib-id><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="acn352010-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acn352010-cr-0002" contrib-type="author"><name><surname>Wang</surname><given-names>Yan</given-names></name><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352010-cr-0003" contrib-type="author"><name><surname>McDonough</surname><given-names>Jennifer</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9809-2289</contrib-id><xref rid="acn352010-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acn352010-cr-0004" contrib-type="author"><name><surname>Zhu</surname><given-names>Meina</given-names></name><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352010-cr-0005" contrib-type="author"><name><surname>Burns</surname><given-names>Travis</given-names></name><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352010-cr-0006" contrib-type="author"><name><surname>Al Ramel</surname><given-names>Najmah</given-names></name><xref rid="acn352010-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acn352010-cr-0007" contrib-type="author"><name><surname>Dehghani</surname><given-names>Ali</given-names></name><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352010-cr-0008" contrib-type="author"><name><surname>Guo</surname><given-names>Fuzheng</given-names></name><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn352010-cr-0009" contrib-type="author" corresp="yes"><name><surname>Pleasure</surname><given-names>David</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9122-1268</contrib-id><xref rid="acn352010-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn352010-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>depleasure@ucdavis.edu</email></address></contrib></contrib-group><aff id="acn352010-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>UC Davis School of Medicine</institution>
<city>Sacramento</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="acn352010-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Shriners Hospital for Children</institution>
<city>Sacramento</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="acn352010-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Physiology</named-content>
<institution>David Geffen School of Medicine, UCLA</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="acn352010-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Biological Sciences</named-content>
<institution>Kent State University</institution>
<city>Kent</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
David Pleasure, Department of Neurology, UC Davis School of Medicine, c/o Shriners Hospital, 2425 Stockton Boulevard, Sacramento, CA 95817, USA. Tel: 916&#x2010;508&#x2010;4305, Fax: 916&#x2010;453&#x2010;2288, E&#x2010;mail: <email>depleasure@ucdavis.edu</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2024</year></pub-date><volume>11</volume><issue seq="220">4</issue><issue-id pub-id-type="doi">10.1002/acn3.v11.4</issue-id><fpage>1059</fpage><lpage>1062</lpage><history>
<date date-type="rev-recd"><day>22</day><month>12</month><year>2023</year></date>
<date date-type="received"><day>15</day><month>9</month><year>2023</year></date>
<date date-type="accepted"><day>19</day><month>1</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2024 American Neurological Association--><copyright-statement content-type="article-copyright">&#xA9; 2024 The Authors. <italic toggle="yes">Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals LLC on behalf of American Neurological Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACN3-11-1059.pdf"/><abstract><title>Abstract</title><p>Canavan disease is a leukodystrophy caused by <italic toggle="no">ASPA</italic> mutations that diminish oligodendroglial aspartoacylase activity, and is characterized by markedly elevated brain concentrations of the aspartoacylase substrate N&#x2010;acetyl&#x2010;<sc>l</sc>&#x2010;aspartate (NAA) and by astroglial and intramyelinic vacuolation. Astroglia express NaDC3 (encoded by <italic toggle="no">SLC13A3</italic>), a sodium&#x2010;coupled transporter for NAA and other dicarboxylates. Astroglial conditional <italic toggle="no">Slc13a3</italic> deletion in aspartoacylase&#x2010;deficient Canavan disease model mice (&#x201C;CD mice&#x201D;) reversed brain NAA elevation and improved motor function. These results demonstrate that astroglial NaDC3 contributes to brain NAA elevation in CD mice, and suggest that suppressing astroglial NaDC3 activity would ameliorate human Canavan disease.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institutes of Health
</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R21NS117386</award-id><award-id>R21NS133881</award-id></award-group><award-group id="funding-0002"><funding-source>the National Center for Advancing Translational Sciences, National Institutes of Health</funding-source><award-id>TL1 TR001861</award-id><award-id>UL1 TR001860</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Shriners Hospitals for Children
</institution><institution-id institution-id-type="doi">10.13039/100011781</institution-id></institution-wrap></funding-source></award-group><funding-statement>This work was funded by <funding-source><institution-wrap><institution>National Institutes of Health
</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source> grants <award-id>R21NS117386</award-id> and <award-id>R21NS133881</award-id>; <funding-source>the National Center for Advancing Translational Sciences, National Institutes of Health</funding-source> grants <award-id>TL1 TR001861</award-id> and <award-id>UL1 TR001860</award-id>; <funding-source><institution-wrap><institution>Shriners Hospitals for Children
</institution><institution-id institution-id-type="doi">10.13039/100011781</institution-id></institution-wrap></funding-source>.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="1062"/><word-count count="2620"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.0 mode:remove_FC converted:17.04.2024</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body id="acn352010-body-0001">
    <sec id="acn352010-sec-0001">
      <title>Introduction</title>
      <p>Canavan disease is a recessively inherited early onset leukodystrophy caused by inactivating <italic toggle="yes">ASPA</italic> mutations that diminish oligodendroglial aspartoacylase activity.<xref rid="acn352010-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The concentration of the aspartoacylase substrate N&#x2010;acetyl&#x2010;<sc>l</sc>&#x2010;aspartate in brain ([NAA<sub>B</sub>]) is elevated in these patients, who fail to attain or maintain motor and intellectual milestones, are often neonatally megalencephalic, and frequently develop seizures.<xref rid="acn352010-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="acn352010-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Neuroimaging reveals brain white matter signal abnormalities consistent with cytotoxic edema, and autopsy demonstrates astroglial and intramyelinic vacuolation.<xref rid="acn352010-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="acn352010-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Mice homozygous for the <italic toggle="yes">Aspa</italic> nonsense mutation <italic toggle="yes">nur7</italic> (&#x201C;CD mice&#x201D;) lack detectable aspartoacylase, demonstrate a typically twofold or greater elevation in [NAA<sub>B</sub>], and develop motor deficits by postnatal day 21.<xref rid="acn352010-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p>
      <p>NaDC3, encoded by <italic toggle="yes">SLC13A3</italic> (<italic toggle="yes">Slc13a3</italic> in mice), is a plasma membrane Na<sup>+</sup>&#x2010;coupled dicarboxylate transporter that can mediate intracellular accumulation of NAA and Na<sup>+</sup> from the medium by cultured rat astroglia.<xref rid="acn352010-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="acn352010-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<italic toggle="yes">Slc13a3</italic> is also expressed by meningeal cells and renal proximal tubular epithelium.<xref rid="acn352010-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="acn352010-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> To explore the specific pathophysiological significance of astroglial NaDC3 in Canavan disease, we examined the effects of astroglial <italic toggle="yes">Slc13a3</italic> conditional knockout on [NAA<sub>B</sub>] and motor function in young adult CD mice.</p>
    </sec>
    <sec sec-type="methods" id="acn352010-sec-0002">
      <title>Methods</title>
      <p>
<italic toggle="yes">Slc13a3</italic>
<sup>
<italic toggle="yes">flox</italic>
</sup> mice were derived from <italic toggle="yes">Slc13a3</italic> knockout first mice (MMRRC.049665&#x2010;UCD) by crossing with Flp1 deleter mice (Jackson Laboratory #009086). The <italic toggle="yes">Slc13a3</italic>
<sup>
<italic toggle="yes">flox</italic>
</sup> mice were then crossed with <italic toggle="yes">Aspa</italic>
<sup>
<italic toggle="yes">nur7</italic>
</sup> mice (Jackson Laboratory #008607) and with <italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup> mice (Jackson Laboratory #012849) to yield the &#x201C;CDcKO&#x201D; mice used in this study, which were homozygous for <italic toggle="yes">Aspa</italic>
<sup>
<italic toggle="yes">nur7</italic>
</sup> and <italic toggle="yes">Slc13a3</italic>
<sup>
<italic toggle="yes">flox</italic>
</sup> and carried one copy of the <italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup> transgene (Fig.&#xA0;<xref rid="acn352010-fig-0001" ref-type="fig">1A</xref>). Control (&#x201C;CDctrl&#x201D;) mice were bred to also be homozygous for <italic toggle="yes">Aspa</italic>
<sup>
<italic toggle="yes">nur7</italic>
</sup>, but to lack either <italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup> or <italic toggle="yes">Slc13a3</italic>
<sup>
<italic toggle="yes">flox</italic>
</sup> alleles. Mouse genotypes were validated by qPCR. All mice were maintained on a C57BL6 background in an AAALAC&#x2010;certified vivarium. Both male and female mice were employed. All animal procedures were conducted in accord with a UC Davis IACUC&#x2010;approved protocol.</p>
      <fig position="float" fig-type="Figure" id="acn352010-fig-0001">
        <label>Figure 1</label>
        <caption>
          <p>Panel A: <italic toggle="yes">Slc13a3</italic> conditional deletion construct. Panel B: Experimental design. Panel C: qRT/PCR <italic toggle="yes">Slc13a3</italic> mRNA results in cerebellum, meninges, and kidney of CDcKO (dark green) and CDctrl (light green) mice, normalized to Hsp90 mRNA. Panel D: Astrocytes were isolated using MACS with Anti&#x2010;ACSA&#x2010;2 MicroBeads (ACSA&#x2010;2: astrocyte cell surface antigen&#x2010;2) according to the manufacturer's instruction (Miltenyi Biotec)&#xA0;The flow&#x2010;through, devoid of ACSA&#x2010;2&#x2010;positive astrocytes, was collected as the astrocyte&#x2010;depleted fraction. Panel E: Quantitative PCR was used to quantify the astrocyte marker <italic toggle="yes">Aldh1L1</italic> mRNA<xref rid="acn352010-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> (forward primer 5&#x2032;&#x2010;CAGGAGGTTTACTGCCAGCTA&#x2010;3&#x2032; and reverse primer 5&#x2032;&#x2010;CACGTTGAGTTCTGCACCCA&#x2010;3&#x2032;) and <italic toggle="yes">Slc13a3</italic> mRNA (see Methods) in the astrocyte&#x2010;enriched and astrocyte&#x2010;depleted fractions. Each circle represents results in an individual mouse (solid circles male and open circles female). Column heights represent means, and vertical brackets denote SEMs. *<italic toggle="yes">p</italic>&#x2009;=&#x2009;0.0265, ***<italic toggle="yes">p</italic>&#x2009;=&#x2009;0.0003, Student's <italic toggle="yes">t</italic>&#x2010;test.</p>
        </caption>
        <graphic xlink:href="ACN3-11-1059-g002" position="anchor" id="jats-graphic-1"/>
      </fig>
      <p>An accelerating rotarod apparatus was used to assess motor function in non&#x2010;tamoxifen&#x2010;treated CD mice, tamoxifen&#x2010;treated CD/<italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup>
<italic toggle="yes">/Slc13a3</italic>
<sup>flox/flox</sup> mice (&#x201C;CDcKO&#x201D; mice), and tamoxifen&#x2010;treated CDctrl mice just before and at intervals after a 5&#x2009;day course of tamoxifen (1.5&#x2009;mg/50&#x2009;&#x3BC;L sunflower oil/day) (Fig.&#xA0;<xref rid="acn352010-fig-0001" ref-type="fig">1B</xref>).<xref rid="acn352010-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Eight weeks post&#x2010;tamoxifen, the mice were euthanized; meninges were carefully dissected away from underlying brain; and cerebella, forebrain, meninges, and kidneys were separately flash&#x2010;frozen and stored at &#x2212;80&#xB0;C. <italic toggle="yes">Slc13a3</italic> recombination in cerebellar parenchyma, meninges, and kidney was assessed by qPCR, using the <italic toggle="yes">Slc13a3</italic> cDNA primers (forward primer 5&#x2032;&#x2010;TCTCAGTGTAAGAAGCGC&#x2010;3&#x2032; and reverse primer 5&#x2032;&#x2010;CACTGCCTGGGTTCAAAGTC&#x2010;3&#x2032;). Results were normalized to <italic toggle="yes">Hsp90 mRNA</italic> (forward primer 5&#x2032;&#x2010;AAACAAGGAGATTTTCCTCCGC&#x2010;3&#x2032; and reverse primer 5&#x2032;&#x2010;CCGTCAGGCTCTCATATCGAAT&#x2010;3&#x2032;). Forebrain samples from euthanized 16&#x2009;week old CDcKO and CDctrl mice were assayed for NAA by HPLC<xref rid="acn352010-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> or enzymatically dissociated prior to magnetic activated cell sorting (MACS)<xref rid="acn352010-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> to prepare astrocyte&#x2010;enriched and astrocyte&#x2010;depleted cell fractions for qPCR quantifications of <italic toggle="yes">Slc13a3</italic> mRNA and of <italic toggle="yes">Aldh1L1</italic> mRNA. Cryostat forebrain and cerebellar sections from 16&#x2010;week&#x2010;old wild&#x2010;type, CDcKO and CDctrl mice were employed to quantify cerebellar vacuolation.</p>
    </sec>
    <sec sec-type="results" id="acn352010-sec-0003">
      <title>Results</title>
      <p>Tamoxifen activation of <italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup> elicited a 61% reduction in <italic toggle="yes">Slc13a3</italic> mRNA abundance in cerebellar parenchyma of CDcKO mice, but did not significantly alter cerebellar parenchymal <italic toggle="yes">Slc13a3</italic> mRNA abundance in CDctrl mice, nor in the meninges and kidneys of either CDcKO or CDctrl mice (Fig.&#xA0;<xref rid="acn352010-fig-0001" ref-type="fig">1C</xref>). Magnetic activated cell sorting was used to prepare astroglia&#x2010;enriched (&#x201C;astro<sup>+</sup>&#x201D;) and astrocyte&#x2010;depleted (&#x201C;astro<sup>&#x2212;</sup>&#x201D;) cell fractions from forebrains of 16&#x2010;week&#x2010;old wild&#x2010;type (WT) mice. Abundances of both <italic toggle="yes">Slc13a3</italic> mRNA and mRNA encoding the astrocyte marker Aldh1L1<xref rid="acn352010-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> were markedly greater in the astro<sup>+</sup> fraction than in the astro<sup>&#x2212;</sup> fraction, and <italic toggle="yes">Slc13a3</italic> mRNA abundance was 56% lower in the astroglial fraction from tamoxifen&#x2010;treated than from non&#x2010;tamoxifen&#x2010;treated <italic toggle="yes">GFAPcre</italic>
<sup>ERT2</sup>/<italic toggle="yes">Slc13a3</italic>
<sup>flox/flox</sup> mice (Fig.&#xA0;<xref rid="acn352010-fig-0001" ref-type="fig">1D</xref>).</p>
      <p>At age 16&#x2009;weeks, [NAA<sub>B</sub>] in the tamoxifen&#x2010;treated CDcKO mice was 55% below that in the tamoxifen&#x2010;treated CDctrl mice (Fig.&#xA0;<xref rid="acn352010-fig-0002" ref-type="fig">2A</xref>), but the extent of cerebellar vacuolation in the CDcKO mice did not differ significantly from that in the CDctrl mice (Fig.&#xA0;<xref rid="acn352010-fig-0002" ref-type="fig">2B</xref>). Accelerating rotarod retention times in CDcKO mice had significantly increased by 1&#x2009;week after completion of tamoxifen administration, and remained substantially elevated through 7 additional weeks of observation, whereas accelerating rotarod retention times in CD mice not treated with tamoxifen and in CDctrl mice treated with tamoxifen remained consistent throughout the entire period of testing (Fig.&#xA0;<xref rid="acn352010-fig-0002" ref-type="fig">2C</xref>).</p>
      <fig position="float" fig-type="Figure" id="acn352010-fig-0002">
        <label>Figure 2</label>
        <caption>
          <p>Panel A: [NAA<sub>B</sub>] of CDcKO (dark green) and CDctrl (light green) mice. **<italic toggle="yes">p</italic>&#x2009;=&#x2009;0.0031, Student's <italic toggle="yes">t</italic>&#x2010;test. Panel B: Cerebellar vacuolation in CDcKO and CDctrl mice, showing no significant difference between the two groups. Panel C: Accelerating rotarod retention times of CDcKO and CDctrl mice. Column heights represent means, and vertical brackets denote SEMs. *<italic toggle="yes">p</italic>&#x2009;&lt;&#x2009;0.05; **<italic toggle="yes">p</italic>&#x2009;=&#x2009;0.0043; ***<italic toggle="yes">p</italic>&#x2009;&lt;&#x2009;0.0001, comparisons by two&#x2010;way repeated measures ANOVA.</p>
        </caption>
        <graphic xlink:href="ACN3-11-1059-g001" position="anchor" id="jats-graphic-3"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="acn352010-sec-0004">
      <title>Discussion</title>
      <p>Prior studies have demonstrated that lowering [NAA<sub>B</sub>] by inhibiting neuronal NAA synthesis can prevent or reverse brain vacuolation and neuronal dendritic shortening in CD mice.<xref rid="acn352010-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="acn352010-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="acn352010-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> More recently, whole body NaDC3 ablation achieved by constitutive <italic toggle="yes">Slc13a3</italic> deletion was also found to prevent [NAA<sub>B</sub>] elevation and leukodystrophy in CD mice.<xref rid="acn352010-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> But that study did not illuminate the specific role of astroglial NaDC3, versus NaDC3 encoded by meningeal and renal <italic toggle="yes">Slc13a3</italic>,<xref rid="acn352010-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> in mediating [NAA<sub>B</sub>] elevation and eliciting clinical neurological deficits in this murine Canavan disease model. We addressed this issue by testing the effects of astroglial conditional <italic toggle="yes">Slc13a3</italic> deletion in young adult CD mice on [NAA<sub>B</sub>], brain vacuolation, and motor function.</p>
      <p>Gene recombination elicited by <italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup> in the adult murine CNS is restricted largely to astroglia.<xref rid="acn352010-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> In the present study, the abundance of <italic toggle="yes">Slc13a3</italic> mRNA was substantially lower in whole cerebellar parenchyma of 16&#x2010;week&#x2010;old CDcKO than CDctrl mice, but was not lowered in CDcKO meninges or kidneys. MACS results indicated that <italic toggle="yes">Slc13a3</italic> mRNA expression in brain parenchyma was confined largely to astroglia, and was diminished in astroglia by more than 50% by CDcKO. We concluded, therefore, that mouse brain <italic toggle="yes">Slc13a3</italic> knockdown elicited in tamoxifen&#x2010;treated CD/<italic toggle="yes">GFAPcreER</italic>
<sup>
<italic toggle="yes">T2</italic>
</sup>
<italic toggle="yes">/Slc13a3</italic>
<sup>flox/flox</sup> mice was largely or wholly confined to astroglia.</p>
      <p>The substantially lower [NAA<sub>B</sub>] in the 16&#x2009;week old CDcKO than CDctrl mice supports the concept that astroglial NaDC3 activity contributes to brain NAA elevation in Canavan disease. Though astroglial conditional <italic toggle="yes">Slc13a3</italic> knockout initiated at age 8&#x2009;weeks did not yield a reduction in the extent of cerebellar vacuolation at age 16&#x2009;weeks, accelerating rotarod analysis demonstrated a rapid and long&#x2010;lasting improvement in motor function in the CDcKO mice. A similarly rapid initial improvement in motor function was previously observed in young adult CD mice when [NAA<sub>B</sub>] was lowered by inhibiting brain NAA synthesis via intrathecal administration of an <italic toggle="yes">Nat8l</italic> antisense oligonucleotide.<xref rid="acn352010-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Together, these observations strengthen support for the pathophysiological significance of elevated [NAA<sub>B</sub>] in Canavan disease.</p>
      <p>Are <italic toggle="yes">SLC13A3</italic> and NaDC3 suitable targets for treating Canavan disease? Constitutive <italic toggle="yes">Slc13a3</italic> deletion in wild&#x2010;type mice has no obvious phenotypic effects other than increasing urinary NAA output,<xref rid="acn352010-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> but, in humans, mutations that inactivate both alleles of <italic toggle="yes">SLC13A3</italic> increase susceptibility to viral infection&#x2010;triggered acute reversible leukoencephalopathy.<xref rid="acn352010-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Thus, measures designed to suppress global, or astrocyte&#x2010;specific, <italic toggle="yes">SLC13A3</italic> expression and NaDC3 activity in infants and children with Canavan disease may prove useful in limiting [NAA<sub>B</sub>] elevation and preventing or ameliorating their neurological deficits, but might also increase their risk for developing reversible leukoencephalopathy.</p>
    </sec>
    <sec id="acn352010-sec-0119">
      <title>Author Contributions</title>
      <p>VLH and DP wrote the first draft. All authors provided critical review and feedback and approved the final draft. VLH, YW, JM, and FG provided statistical analysis, VLH, YW, and DP designed the work. VLH, YW, JM, MZ, TB, NR, AD and DP performed and interpreted the studies.</p>
    </sec>
    <sec sec-type="COI-statement" id="acn352010-sec-0006">
      <title>Conflict of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack id="acn352010-sec-0005">
      <title>Acknowledgments</title>
      <p>This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR001860 and linked award TL1 TR001861 (VLH); National Institutes of Health grants R21NS117386 (DP) and R21NS133881 (DP); and by funds from Shriners Hospitals for Children.</p>
    </ack>
    <ref-list content-type="cited-references" id="acn352010-bibl-0001">
      <title>References</title>
      <ref id="acn352010-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0001">
<string-name>
<surname>Wei</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Moffett</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Amanat</surname>
<given-names>M</given-names>
</string-name>, et&#xA0;al. <article-title>The pathogenesis of, and pharmacological treatment for, Canavan disease</article-title>. <source>Drug Discov Today</source>. <year>2022</year>;<volume>27</volume>:<fpage>2467</fpage>&#x2010;<lpage>2483</lpage>.<pub-id pub-id-type="pmid">35636725</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0002">
<string-name>
<surname>Bley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Denecke</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kohlschutter</surname>
<given-names>A</given-names>
</string-name>, et&#xA0;al. <article-title>The natural history of Canavan disease: 23 new cases and comparison with patients in the literature</article-title>. <source>Orphanet J Rare Dis</source>. <year>2021</year>;<volume>16</volume>:<fpage>227</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13023-020-01659-3</pub-id>
<pub-id pub-id-type="pmid">34011350</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0003">
<string-name>
<surname>Merrill</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Longo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nonkowsky</surname>
<given-names>J</given-names>
</string-name>. <article-title>Cytotoxic edema and diffusion restriction as an early pathoradiologic marker in Canavan disease; case report and review of the literature</article-title>. <source>Orphanet J Rare Dis</source>. <year>2016</year>;<volume>11</volume>:<fpage>169</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s3023-016-0549-1</pub-id>
<pub-id pub-id-type="pmid">27927234</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0004">
<string-name>
<surname>Adachi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schneck</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cara</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Volk</surname>
<given-names>B</given-names>
</string-name>. <article-title>Spongy degeneration of the central nervous system (Van Bogaert and Bertrand type; Canavan's disease). A review</article-title>. <source>Hum Pathol</source>. <year>1973</year>;<volume>4</volume>:<fpage>331</fpage>&#x2010;<lpage>347</lpage>.<pub-id pub-id-type="pmid">4593851</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0005">
<string-name>
<surname>Traka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wollmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cerda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dugas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barres</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Popko</surname>
<given-names>B</given-names>
</string-name>. <article-title>
<italic toggle="yes">Nur7</italic> is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>:<fpage>11537</fpage>&#x2010;<lpage>11549</lpage>.<pub-id pub-id-type="pmid">18987190</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0006">
<string-name>
<surname>Huang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kekuda</surname>
<given-names>R</given-names>
</string-name>, et&#xA0;al. <article-title>Transport of N&#x2010;acetylaspartate by the Na<sup>+</sup>&#x2010;dependent high&#x2010;affinity dicarboxylate transporter NaDC3 and its relevance to the expression of the transporter in the brain</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2000</year>;<volume>295</volume>:<fpage>392</fpage>&#x2010;<lpage>403</lpage>.<pub-id pub-id-type="pmid">10992006</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0007">
<string-name>
<surname>Fujita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tatsukawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yodoya</surname>
<given-names>E</given-names>
</string-name>, et&#xA0;al. <article-title>Transport characteristics of N&#x2010;acetyl&#x2010;<sc>l</sc>&#x2010;aspartate in rat astrocytes: involvement of sodium&#x2010;coupled high&#x2010;affinity carboxylate transporter NaC3/NaDC3&#x2010;mediated transport system</article-title>. <source>J Neurochem</source>. <year>2005</year>;<volume>93</volume>:<fpage>706</fpage>&#x2010;<lpage>714</lpage>.<pub-id pub-id-type="pmid">15836629</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0008">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hull</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sternbach</surname>
<given-names>B</given-names>
</string-name>, et&#xA0;al. <article-title>Ablating the transporter sodium&#x2010;dependent dicarboxylate transporter 3 prevents leukodystrophy in Canavan disease mice</article-title>. <source>Ann Neurol</source>. <year>2021</year>;<volume>90</volume>:<fpage>845</fpage>&#x2010;<lpage>850</lpage>.<pub-id pub-id-type="pmid">34498299</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0009">
<string-name>
<surname>Cahoy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Emery</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kaushal</surname>
<given-names>A</given-names>
</string-name>, et&#xA0;al. <article-title>A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>:<fpage>264</fpage>&#x2010;<lpage>278</lpage>.<pub-id pub-id-type="pmid">18171944</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0010">
<string-name>
<surname>Brooks</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dunnett</surname>
<given-names>S</given-names>
</string-name>. <article-title>Tests to assess motor phenotype in mice: a user's guide</article-title>. <source>Nature Rev Neurosci</source>. <year>2009</year>;<volume>10</volume>:<fpage>519</fpage>&#x2010;<lpage>529</lpage>.<pub-id pub-id-type="pmid">19513088</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0011">
<string-name>
<surname>Jan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Won</surname>
<given-names>J</given-names>
</string-name>. <article-title>Methodological comparison of FACS and MACS isolation of enriched microglia and astrocytes from mouse brain</article-title>. <source>J Immunol Methods</source>. <year>2020</year>;<volume>486</volume>:<elocation-id>112834</elocation-id>.<pub-id pub-id-type="pmid">32810482</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0012">
<string-name>
<surname>Guo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bannerman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mills Ho</surname>
<given-names>E</given-names>
</string-name>, et&#xA0;al. <article-title>Ablating N&#x2010;acetylaspartate prevents leukodystrophy in a Canavan disease model</article-title>. <source>Ann Neurol</source>. <year>2015</year>;<volume>77</volume>:<fpage>884</fpage>&#x2010;<lpage>888</lpage>.<pub-id pub-id-type="pmid">25712859</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0013">
<string-name>
<surname>Maier</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang&#x2010;Eckhardt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gieselmann</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>M</given-names>
</string-name>. <article-title>N&#x2010;acetylaspartate synthase deficiency corrects the myelin phenotype in a Canavan disease mouse model but does not affect survival time</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>:<fpage>14501</fpage>&#x2010;<lpage>14516</lpage>.<pub-id pub-id-type="pmid">26511242</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0014">
<string-name>
<surname>Hull</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Burns</surname>
<given-names>T</given-names>
</string-name>, et&#xA0;al. <article-title>Antisense oligonuceotide reverses leukodystrophy in Canavan disease mice</article-title>. <source>Ann Neurol</source>. <year>2020</year>;<volume>87</volume>:<fpage>480</fpage>&#x2010;<lpage>485</lpage>.<pub-id pub-id-type="pmid">31925837</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0015">
<string-name>
<surname>Guo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>J</given-names>
</string-name>, et&#xA0;al. <article-title>Macroglial plasticity and the origins of reactive astroglia in experimental autoimmune encephalomyelitis</article-title>. <source>J Neurosci</source>. <year>2011</year>;<volume>31</volume>:<fpage>11914</fpage>&#x2010;<lpage>11928</lpage>.<pub-id pub-id-type="pmid">21849552</pub-id>
</mixed-citation>
      </ref>
      <ref id="acn352010-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="acn352010-cit-0016">
<string-name>
<surname>Dewulf</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wiame</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dorboz</surname>
<given-names>I</given-names>
</string-name>, et&#xA0;al. <article-title>SLC13A3 variants cause reversible leukoencephalopathy and a&#x2010;ketoglutarate accumulation</article-title>. <source>Ann Neurol</source>. <year>2019</year>;<volume>85</volume>:<fpage>385</fpage>&#x2010;<lpage>395</lpage>.<pub-id pub-id-type="pmid">30635937</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>